Arix Bioscience-backed Artios secures USD153m in Series C financing led by Omega Funds and TCG X
Artios Pharma Limited (Artios), a DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, has completed a USD153 million (GBP110 million) Series C financing to fund further development of its

